Our flagship project, VolTrac, represents a pioneering leap in non-invasive diagnostics. VolTrac is a portable, handheld device powered by proprietary chemiresistive sensor technology capable of detecting VOCs at sub-parts-per-billion (PPB) sensitivity. It enables rapid, point-of-care screening for a variety of medical conditions using exhaled breath or environmental samples, thereby addressing major healthcare challenges related to accessibility, speed, and cost. The platform is designed for mass screening, early disease detection, and even contraband (narcotics) identification—serving both healthcare and law enforcement sectors.
Startup Description
Accubits Invent Pvt Ltd is at the forefront of technological innovation, with a strong commitment to research and development in material sciences, biotechnology, and AI-driven diagnostics. The company’s ongoing flagship project, VolTrac, exemplifies this R&D focus, targeting the development of non-invasive, ultra-sensitive VOC detection platforms for early disease diagnosis, mass screening, and contraband identification. Beyond VolTrac, Accubits Invent is actively engaged in R&D initiatives addressing infectious diseases, metabolic disorders, and environmental monitoring. The company has established collaborative partnerships with leading healthcare organisations such as CIPLA for TB detection. Drawing inspiration from national innovation priorities, Accubits Invent consistently invests in lab infrastructure, advanced sensor technologies, and translational research. Invent has also been an active participant of the Drug Discovery Hackathon, conducted by GoI during the COVID breakout. We have also launched an open source protein interaction database to accelerate innovation. This deep-rooted R&D culture ensures that the company not only delivers innovative solutions like VolTrac but also sustains long-term impact in healthcare, public health, and security sectors.
Business Model
VolTrac’s roadmap is structured into three key phases:
Phase I (Years 1–2): Product development supported by a TDB grant and internal funding. Goal: develop and validate the device.
Phase II (Year 3): Limited commercial release via pilot institutions (diabetes clinic, pediatric hospital, etc.) to generate real-world data and establish manufacturing. Target: ~50 units deployed. Begin modest revenue, marketing, and scale-up planning.
Phase III (Years 4–5): Full-scale production ramp-up. Engage large customers (hospital chains, state health programs), targeting hundreds of unit sales in Year 4, scaling to 1000+ by Year 5. Explore licensing with global firms or PSUs for faster expansion.
Distribution: Use both direct sales (institutions, government) and distributor networks for smaller clinics. CIPLA may act as distributor or co-branding partner to enhance reach.
Revenue Streams: Hardware sales, consumables (mouthpieces, sensors), and service contracts. Potential for cloud-based data subscription in future.
Scaling & Expansion: Scale via contract manufacturing when demand rises. Explore Asian & African markets via global health programs.
Future Focus: Reinvest in R&D for new tests and applications, keeping VolTrac ahead in VOC-based diagnostics. Aim for positive cash flow by Year 5 and expand global footprint.
Customers
based in
India
Business
Modal Type
Health care centre, State Health Programs
Type of
Sales
B2B, B2C
Competitors
In the emerging sector of breath-based diagnostics in India, several innovative players are actively competing. Notable among them is Kozhnosys, known for their product CanScan, an advanced breath analyser employing chemiresistive sensor technology to detect volatile organic compounds (VOCs). Kozhnosys primarily targets early detection of breast and lung cancers. Their approach combines nanotechnology and artificial intelligence to achieve sensitivity and specificity; however, they are still in various stages of clinical validation.
Respyr is another prominent startup utilising breath-based diagnostics. Their focus is predominantly on respiratory diseases, gut health and liver health. Respyr employs advanced electrochemical sensing and machine learning techniques, aiming to facilitate portable, non-invasive detection and lifestyle monitoring. Like Kozhnosys, their products are undergoing clinical validation and are yet to see widespread commercial adoption.
Beyond these startups, major Indian pharmaceutical players such as Cipla and global entities like Owlstone Medical indirectly compete by focusing on VOC biomarkers, albeit often through partnerships rather than direct products currently in the market.
Teams
Nidhin Sreekumar
Managing Director
Ditto P S
AI & Programing Head
Achyuthanand R L
Finance & Compliance Head
Aswathy Udayan
Scientist
Sajini S S
Research Assistant
Gayathri S S
Research Assistant
Are all the founders full-time on this
project?
Yes
Looking for an
opportunity to invest in companies
like Accubits Invent?
